Merck (NYSE: MRK ) , one of the biggest drugmakers on the planet, may not be among the most exciting or innovative health care companies, but it is often favored by long-term investors. In this video, health care analyst Max Macaluso dives into three compelling reasons why investors should think about buying Merck.
For nearly 100 years, Merck's cutting-edge research has led to a number of medical breakthroughs. Today, however, this pharma stalwart is staring down a steep patent cliff and facing generic competition for its top-selling drug. For more detailed information, make sure you take a look at our brand new premium research report today. Our senior biotech analyst Brian Orelli, Ph.D., walks you through both the opportunities and threats facing Merck, and the report comes with a full 12 months of updates. Claim your copy now by clicking here.